JP2010517544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010517544A5 JP2010517544A5 JP2009548617A JP2009548617A JP2010517544A5 JP 2010517544 A5 JP2010517544 A5 JP 2010517544A5 JP 2009548617 A JP2009548617 A JP 2009548617A JP 2009548617 A JP2009548617 A JP 2009548617A JP 2010517544 A5 JP2010517544 A5 JP 2010517544A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- hcmv
- chimeric
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000000890 antigenic effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000003149 assay kit Methods 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07101864 | 2007-02-07 | ||
| PCT/EP2008/000876 WO2008095677A1 (en) | 2007-02-07 | 2008-02-05 | Recombinant antigens of human cytomegalovirus (hcmv) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010517544A JP2010517544A (ja) | 2010-05-27 |
| JP2010517544A5 true JP2010517544A5 (OSRAM) | 2011-03-24 |
Family
ID=38229391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548617A Pending JP2010517544A (ja) | 2007-02-07 | 2008-02-05 | ヒトサイトメガロウイルス（ｈｃｍｖ）の組換え抗原 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100068229A1 (OSRAM) |
| EP (1) | EP2114991A1 (OSRAM) |
| JP (1) | JP2010517544A (OSRAM) |
| KR (1) | KR20090126256A (OSRAM) |
| CN (1) | CN101605808A (OSRAM) |
| AU (1) | AU2008213356A1 (OSRAM) |
| BR (1) | BRPI0807095A2 (OSRAM) |
| CA (1) | CA2677455A1 (OSRAM) |
| EA (1) | EA200970731A1 (OSRAM) |
| IL (1) | IL200187A0 (OSRAM) |
| MX (1) | MX2009008248A (OSRAM) |
| SG (1) | SG178761A1 (OSRAM) |
| WO (1) | WO2008095677A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5833565B2 (ja) | 2009-12-23 | 2015-12-16 | ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ | ヒトサイトメガロウイルスに対する結合メンバー |
| JP5712513B2 (ja) * | 2010-07-07 | 2015-05-07 | 富士レビオ株式会社 | ヒトサイトメガロウイルス感染の検出方法 |
| US20130288389A1 (en) * | 2011-01-18 | 2013-10-31 | Prionics Ag | Methods for amplification and detection of prions |
| CN102816246B (zh) * | 2012-09-04 | 2014-07-23 | 成都蓉生药业有限责任公司 | 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2019020480A1 (en) * | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL60184A (en) * | 1979-05-31 | 1984-05-31 | Schering Ag | Process for the specific cleavage of protein sequences from proteins |
| RU2023448C1 (ru) * | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| CA2050425A1 (en) * | 1990-09-03 | 1992-03-04 | Yoshiaki Uda | Pharmaceutical composition and its mucous use |
| EP2156845A1 (en) * | 1992-05-23 | 2010-02-24 | GlaxoSmithKline Biologicals SA | Combined vaccines comprising hepatitis B surface antigen and other antigens |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| AU735981B2 (en) * | 1996-07-12 | 2001-07-19 | Akzo Nobel N.V. | Peptide reagent for the detection of human cytomegalovirus (CMV) |
| US6306404B1 (en) * | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| AT408615B (de) * | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| WO2003010198A1 (en) | 2001-07-26 | 2003-02-06 | Kenton Srl | Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques |
-
2008
- 2008-02-05 KR KR1020097018587A patent/KR20090126256A/ko not_active Withdrawn
- 2008-02-05 WO PCT/EP2008/000876 patent/WO2008095677A1/en not_active Ceased
- 2008-02-05 BR BRPI0807095-4A2A patent/BRPI0807095A2/pt not_active IP Right Cessation
- 2008-02-05 MX MX2009008248A patent/MX2009008248A/es not_active Application Discontinuation
- 2008-02-05 EA EA200970731A patent/EA200970731A1/ru unknown
- 2008-02-05 JP JP2009548617A patent/JP2010517544A/ja active Pending
- 2008-02-05 EP EP08707547A patent/EP2114991A1/en not_active Withdrawn
- 2008-02-05 US US12/525,800 patent/US20100068229A1/en not_active Abandoned
- 2008-02-05 SG SG2012008769A patent/SG178761A1/en unknown
- 2008-02-05 CN CNA2008800045081A patent/CN101605808A/zh active Pending
- 2008-02-05 AU AU2008213356A patent/AU2008213356A1/en not_active Abandoned
- 2008-02-05 CA CA002677455A patent/CA2677455A1/en not_active Abandoned
-
2009
- 2009-07-30 IL IL200187A patent/IL200187A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113321739B (zh) | 一种covid-19亚单位疫苗及其制备方法与应用 | |
| JP2010517544A5 (OSRAM) | ||
| JP2010166921A5 (OSRAM) | ||
| JP2006523453A5 (OSRAM) | ||
| RU2012155702A (ru) | Композиция микробактериальных антигенов | |
| RU2016133598A (ru) | Композиция микобактериального антигена | |
| CN113527522A (zh) | 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗 | |
| EP2254993A1 (en) | Protein nanocarriers, process for obtaining them and applications | |
| RU2012137304A (ru) | Рекомбинантные белки для применения в вакцине, антитела к указанным белкам и диагностические и терапевтические способы, включающие указанное | |
| JP2017521654A5 (OSRAM) | ||
| Lin et al. | Molecular characterization of three major outer membrane proteins, TSA56, TSA47 and TSA22, in Orientia tsutsugamushi | |
| JP3809502B2 (ja) | ハンタウィルス抗原蛋白質およびモノクローナル抗体 | |
| CN106226520B (zh) | 结核分枝杆菌抗原蛋白Rv0865及其B细胞表位肽的应用 | |
| WO2016064060A1 (ko) | Ｐｃｖ２에 특이적인 단일클론항체 및 이를 이용한 ｐｍｗｓ의 진단 방법 | |
| CN102643349B (zh) | 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备 | |
| Shen et al. | DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice | |
| CN102978219A (zh) | 一种弧菌交叉保护性抗原及其制备方法和应用 | |
| WO2022242432A1 (en) | Peptide vaccine for virus infection | |
| JP2004532011A (ja) | 微生物病原体の生物学的に活性な構造体を同定する方法 | |
| Chaudhary et al. | Assessment of Cpa, Scl1 and Scl2 in clinical group A streptococcus isolates and patients from north India: an evaluation of the host pathogen interaction | |
| CN105218668A (zh) | 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用 | |
| CN102169122B (zh) | 一种用于诊断q热病的蛋白组合物 | |
| CN104193827B (zh) | 一种丙型肝炎病毒第一高变区融合抗原及其应用 | |
| CN110958886A (zh) | 恶性疟原虫和间日疟原虫疫苗 | |
| JP2006511442A (ja) | 新規なペプチド組成物及び特にｃ型肝炎ウイルスに対して有効な医薬組成物の製造におけるその使用 |